Alpha-synuclein amyloids catalyze the degradation of ATP and other nucleotides

Intracellular accumulation of alpha-synuclein amyloids is a main pathological hallmark in a subgroup of human neurodegenerative diseases called synucleinopathies. Cell death of energy-deprived dopaminergic neurons causes decreased dopamine levels, which underly many of the neurological symptoms in the most prevalent synucleinopathy, Parkinson's disease. Amyloid-mediated toxicity can proceed via gain-of-function through diverse pathways. In this work, we report that alpha-synuclein amyloids can degrade adenosine triphosphate in a catalytic fashion, producing adenosine diphosphate and adenosine monophosphate. Upon prolonged incubation, all adenosine triphosphate is irreversibly consumed. Furthermore, these amyloids can also degrade all other ribonucleotides with different efficiencies, including guanosine, cytidine, and uridine triphosphates. Our findings uncover a previously unknown gain-of-function for alpha-synuclein amyloids, which may have far reaching implications for ATP and nucleotide metabolism during neurodegeneration in Parkinson's disease and other synucleinopathies.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2025-12-27
DOI
https://doi.org/10.1038/s41598-025-32888-w
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Alpha-synuclein amyloids catalyze the degradation of ATP and other nucleotides

Esteban Nova, Claudio Castillo-Caceres, Rodrigo Diaz-Espinoza
Scientific Reports
Parkinson's Disease Mechanisms and Treatments
article

Alpha-synuclein amyloids catalyze the degradation of ATP and other nucleotides

Esteban Nova, Claudio Castillo-Caceres, Rodrigo Diaz-Espinoza
article en

Abstract

Intracellular accumulation of alpha-synuclein amyloids is a main pathological hallmark in a subgroup of human neurodegenerative diseases called synucleinopathies. Cell death of energy-deprived dopaminergic neurons causes decreased dopamine levels, which underly many of the neurological symptoms in the most prevalent synucleinopathy, Parkinson's disease. Amyloid-mediated toxicity can proceed via gain-of-function through diverse pathways. In this work, we report that alpha-synuclein amyloids can degrade adenosine triphosphate in a catalytic fashion, producing adenosine diphosphate and adenosine monophosphate. Upon prolonged incubation, all adenosine triphosphate is irreversibly consumed. Furthermore, these amyloids can also degrade all other ribonucleotides with different efficiencies, including guanosine, cytidine, and uridine triphosphates. Our findings uncover a previously unknown gain-of-function for alpha-synuclein amyloids, which may have far reaching implications for ATP and nucleotide metabolism during neurodegeneration in Parkinson's disease and other synucleinopathies.

Scientific ReportsVol. 16(1)
Universidad de Santiago de Chile (CL), Metropolitan University of Technology (CL)
Agencia Nacional de Investigación y Desarrollo
Good health and well-being
Openalex Percentile: Top 31%
Parkinson's Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.